Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD | Market Cap | 202.49M +61.2% |
| Revenue (ttm) | n/a |
| Net Income | -36.35M |
| EPS | -0.39 |
| Shares Out | 111.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,232 |
| Average Volume | 113,213 |
| Open | 1.860 |
| Previous Close | 1.870 |
| Day's Range | 1.790 - 1.860 |
| 52-Week Range | 1.225 - 2.330 |
| Beta | 0.42 |
| RSI | 48.25 |
| Earnings Date | May 21, 2026 |
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol fo... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% en...
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites
Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network
Cardiol Therapeutics (CRDL) announced the continued expansion of its pivotal Phase III MAVERIC trial in the U.S., with the planned activation of up to seven additional clinical centers. Patient enroll...
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Lang...
Cardiol Therapeutics Transcript: Study result
2023 was a pivotal year, highlighted by the phase III MAVERIC trial for pericarditis and landmark ARCHER trial results in myocarditis. Strong enrollment, new patent protections, and a robust pipeline position the company for significant growth and strategic partnerships.
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the dev...
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data...
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Cardiol Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted late-stage and early-stage programs targeting inflammation in heart disease, with promising phase II and III data for CardiolRx in pericarditis and myocarditis. CardiolRx aims to fill a major market gap as an oral, non-immunosuppressive therapy.
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the ...
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the ...
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics trading resumes
09:00 EST Cardiol Therapeutics (CRDL) trading resumes
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the d...
Cardiol Therapeutics trading halted, news pending
08:11 EST Cardiol Therapeutics (CRDL) trading halted, news pending
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. Activation of additional top-tier clinical sites in Europe and...
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news
Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript
Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News
Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News
Cardiol Therapeutics Transcript: Study Result
The ARCHER phase II trial in acute myocarditis showed Cardiol Rx significantly reduced left ventricular mass and markers of inflammation, supporting its potential as a novel therapy for inflammatory heart disease. The results reinforce confidence in ongoing phase III trials and future development of next-generation formulations.
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual prop...